Rebecca Heist, MD
Internal Medicine · Boston, MANPI 1184697278
Payments from drug & device makers
Across 552 payments — averaging $31,530 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$5.4M
- Novartis$5.2M
- Daiichi Sankyo Company LTD$4.6M
- Eli Lilly$1M
- Agios Pharmaceuticals, Inc.$312K
- Servier Bioinnovation$257K
- plus $601K from 20 others
Across 7 payments — averaging $494.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$3K
- F. Hoffmann-la Roche AG$515
- Eli Lilly$50
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 256 | $5,444,231 |
| Novartis | 70 | $5,161,397 |
| Daiichi Sankyo Company LTD | 103 | $4,586,710 |
| Eli Lilly | 7 | $1,041,944 |
| Agios Pharmaceuticals, Inc. | 24 | $311,924 |
| Servier Bioinnovation | 8 | $257,326 |
| Roche Products Limited | 8 | $150,310 |
| AbbVie | 16 | $134,317 |
| E.r. Squibb & Sons, L.L.C. | 5 | $92,376 |
| Mirati Therapeutics, Inc. | 12 | $66,063 |
| AstraZeneca | 9 | $54,161 |
| Servier Pharmaceuticals LLC | 3 | $37,132 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22,217 |
| Astrazeneca UK Limited | 7 | $7,832 |
| Novartis Pharma AG | 3 | $6,072 |
| Merck | 4 | $5,728 |
| Pfizer | 2 | $4,600 |
| F. Hoffmann-la Roche AG | 3 | $3,510 |
| Boehringer Ingelheim | 1 | $3,045 |
| EMD Serono, Inc. | 1 | $2,760 |
| Regeneron | 3 | $2,718 |
| Sanofi | 1 | $2,524 |
| Ipsen Biopharmaceuticals, Inc | 1 | $2,500 |
| Gilead | 2 | $1,520 |
| Bristol Myers Squibb | 1 | $1,162 |
| Amgen | 1 | $736 |
How this compares
$17,404,814 in reported general payments places this provider in the 95th percentile of 4,983 internal medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in Boston
- Noopur RajeBoston$19.9M
- Richard PlattBoston$13.5M
- Ryan CorcoranBoston$11.4M
- Elizabeth LeeBoston$9.8M
- Xiuning leBoston$7.9M
- Adrienne WaksBoston$7.3M
- Ibiayi Dagogo-JackBoston$5.8M
- Bilal SiddiquiBoston$5.4M
- David SchenkeinBoston$5.2M
- Elizabeth OdonnellBoston$5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.